PATENT CLAIM ANALYSIS

Application Number: 15750058
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "465000"]

Abstract:
The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof, and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients. The present disclosure is also directed to oral dosage forms, such as tablets or capsules comprising the disclosed blended compositions comprising the disclosed solid dispersion formulations, and the methods for making these solid dispersion formulations, and pharmaceutical compositions

Claim (Index 12):
The oral dosage form according to  claim 11 , wherein the oral dosage form is a tablet, and wherein the tablet is film-coated.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 88.0
- Lexical Diversity: 2.17857
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13156783', '14445970', '14006032', '15607825', '15128714']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7378775422470395
- 35 USC 102 Novelty (BERT): 0.5011164465519615
- Combined Prediction Score: 0.7142014326775317
- Mean Citation Score: 238.31086
- Max Citation Score: 257.35635
- Similarity Product: 192.0611124445796

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test